Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ENB003,Toripalimab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cancer Research Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Coherus Announces Clinical Collaboration for LOQTORZI® with ENB-003 in Ovarian Cancer
Details : A collaboration will evaluate LOQTORZI (toripalimab) with ENB-003 for drug-resistant cancers in the iPROC platform study.
Brand Name : ENB-003
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : ENB003,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cancer Research Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ENB003,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ENB-003 is a selective endothelin B receptor (ETBR) inhibitor that, in preclinical studies, enhanced the efficacy of immunotherapies such as anti-PD-1, anti-CTLA-4 and CAR T across multiple cancer types in preclinical studies.
Brand Name : ENB-003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2023
Lead Product(s) : ENB003,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ENB003,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
Details : ENB-003 is a selective endothelin B receptor (ETBR) inhibitor that, in preclinical studies, enhanced the efficacy of immunotherapies such as anti-PD-1, anti-CTLA-4 and CAR T across multiple cancer types in preclinical studies.
Brand Name : ENB003
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 04, 2022
Lead Product(s) : ENB003,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?